{
  "docId": "019dd923-5fec-763b-95cf-69b322a96f02",
  "docSlug": "xGWB9GQTbCGJgy3pFbHe",
  "documentTitle": "The 24-slide presentation a first-time CEO used to raise $120 million to cure blindness",
  "authorId": "Pitchdecks",
  "authorName": "Aurion Biotech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 4,
  "pageCount": 24,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fec-763b-95cf-69b322a96f02/4",
  "deckHref": "/decks/019dd923-5fec-763b-95cf-69b322a96f02",
  "deckJsonHref": "/decks/019dd923-5fec-763b-95cf-69b322a96f02.json",
  "deckAnchorHref": "/decks/019dd923-5fec-763b-95cf-69b322a96f02#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.13,
        "w": 0.92,
        "x": 0.04,
        "y": 0.195
      },
      "kind": "list",
      "text": "Corneal Endothelial Disease: $4.75B Market; 16M people US/EU/Japan, but few are treated (<70,000 / year); Barriers: limited organ supply, complex surgery, economic disincentives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0955f836-40f0-459f-9d2e-83f51af7c9df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.92,
        "x": 0.04,
        "y": 0.33
      },
      "kind": "list",
      "text": "Clinical Validation: 100+ Patients Treated; Demonstrated efficacy, safety and durability (incl. 5-year follow-up data); Injectable procedure: potential to expand treatment paradigm",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2aa293a9-9085-4e96-a9aa-81e8ae2b5413",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.92,
        "x": 0.04,
        "y": 0.465
      },
      "kind": "list",
      "text": "Well-Defined Regulatory Pathway; Japan: NDA submission 2H 2022; US: IND submission 2H 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48b21bf8-0f50-4302-b2c0-cb088b0232e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.92,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "list",
      "text": "Leverageable Platform; First indication: severe corneal endothelial disease; Additional opportunities: glaucoma, ocular surface disease, AMD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e60f07d-213e-4780-a680-365bd84922de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.92,
        "x": 0.04,
        "y": 0.735
      },
      "kind": "list",
      "text": "Deep Industry Experience; Management: Novartis, Glaukos, Alcon, Biogen, Bausch & Lomb, AcuFocus, CorneaGen, Dendreon; Investors: Flying-L-Partners, Falcon Vision (KKR), Petrichor, Visionary Ventures",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e10393ba-e8f6-4e44-8234-992f2a25619d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "TAM: $4.75B",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-d9f0-76ee-8f9d-07701c65f436",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.38,
        "x": 0.04,
        "y": 0.1
      },
      "kind": "title",
      "text": "Investment Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fec8e9d-e94a-445f-83ef-a2acc8dcaf93",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e2d53748-7789-4382-a3d2-33ce60fe7773",
      "evidence": "The slide provides a concise summary of the investment highlights.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 3,
      "beatId": "bb47959a-5de2-4a91-89d3-6bc98e0ba4dc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 3-4 introduce the problem and market opportunity",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}